Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 322

1.

Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.

Gasperini C, Prosperini L, Tintoré M, Sormani MP, Filippi M, Rio J, Palace J, Rocca MA, Ciccarelli O, Barkhof F, Sastre-Garriga J, Vrenken H, Frederiksen JL, Yousry TA, Enzinger C, Rovira A, Kappos L, Pozzilli C, Montalban X, De Stefano N; and the MAGNIMS Study Group.

Neurology. 2019 Jan 22;92(4):180-192. doi: 10.1212/WNL.0000000000006810. Epub 2018 Dec 26. Review.

PMID:
30587516
2.

Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience.

D'Amico E, Zanghì A, Sciandra M, Borriello G, Callari G, Gallo A, Salemi G, Cottone S, Buccafusca M, Valentino P, Bossio RB, Grimaldi LME, Pozzilli C, Tedeschi G, Zappia M, Patti F.

J Neurol. 2019 Feb;266(2):411-416. doi: 10.1007/s00415-018-9144-9. Epub 2018 Dec 4.

PMID:
30515629
3.

Impact of early diagnosis on clinical characteristics of an Italian sample of people with multiple sclerosis recruited online.

Lavorgna L, Borriello G, Esposito S, Abbadessa G, Capuano R, De Giglio L, Logoteta A, Pozzilli C, Tedeschi G, Bonavita S.

Mult Scler Relat Disord. 2019 Jan;27:239-246. doi: 10.1016/j.msard.2018.10.113. Epub 2018 Nov 5.

PMID:
30419509
4.

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting.

Albrecht P, Bjørnå IK, Brassat D, Farrell R, Feys P, Hobart J, Hupperts R, Linnebank M, Magdič J, Oreja-Guevara C, Pozzilli C, Salgado AV, Ziemssen T.

Ther Adv Neurol Disord. 2018 Oct 5;11:1756286418803248. doi: 10.1177/1756286418803248. eCollection 2018. Review.

5.

Relation between functional connectivity and disability in multiple sclerosis: a non-linear model.

Tommasin S, De Giglio L, Ruggieri S, Petsas N, Giannì C, Pozzilli C, Pantano P.

J Neurol. 2018 Dec;265(12):2881-2892. doi: 10.1007/s00415-018-9075-5. Epub 2018 Oct 1.

PMID:
30276520
6.

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience.

D'Amico E, Zanghì A, Callari G, Borriello G, Gallo A, Graziano G, Valentino P, Buccafusca M, Cottone S, Salemi G, Ragonese P, Bossio RB, Docimo R, Grimaldi LME, Pozzilli C, Tedeschi G, Zappia M, Patti F.

Ther Adv Neurol Disord. 2018 Sep 10;11:1756286418796404. doi: 10.1177/1756286418796404. eCollection 2018.

7.

2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes.

Gaetani L, Prosperini L, Mancini A, Eusebi P, Cerri MC, Pozzilli C, Calabresi P, Sarchielli P, Di Filippo M.

J Neurol. 2018 Nov;265(11):2684-2687. doi: 10.1007/s00415-018-9048-8. Epub 2018 Sep 8.

PMID:
30196327
8.

Predicting the profile of increasing disability in multiple sclerosis.

Tomassini V, Fanelli F, Prosperini L, Cerqua R, Cavalla P, Pozzilli C.

Mult Scler. 2018 Aug 2:1352458518790397. doi: 10.1177/1352458518790397. [Epub ahead of print]

PMID:
30070597
9.

Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study.

Mirabella M, Prosperini L, Lucchini M, Boffa L, Borriello G, Buscarinu MC, Centonze D, Cortese A, De Fino C, De Giglio L, Elia G, Fantozzi R, Ferraro E, Francia A, Galgani S, Gasperini C, Haggiag S, Landi D, Marfia GA, Millefiorini E, Monteleone F, Nociti V, Salvetti M, Sgarlata E, Pozzilli C.

CNS Drugs. 2018 Oct;32(10):963-970. doi: 10.1007/s40263-018-0543-3.

PMID:
30022464
10.

Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis.

Landi D, Ragonese P, Prosperini L, Nociti V, Haggiag S, Cortese A, Fantozzi R, Pontecorvo S, Ferraro E, Buscarinu MC, Mataluni G, Monteleone F, Salvetti M, Di Battista G, Francia A, Millefiorini E, Gasperini C, Mirabella M, Salemi G, Boffa L, Pozzilli C, Centonze D, Marfia GA.

J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1272-1278. doi: 10.1136/jnnp-2018-318468. Epub 2018 Jul 3.

PMID:
29970387
11.

Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.

Prosperini L, Lucchini M, Haggiag S, Bellantonio P, Bianco A, Buscarinu MC, Buttari F, Centonze D, Cortese A, De Giglio L, Fantozzi R, Ferraro E, Fornasiero A, Francia A, Galgani S, Gasperini C, Marfia GA, Millefiorini E, Nociti V, Pontecorvo S, Pozzilli C, Ruggieri S, Salvetti M, Sgarlata E, Mirabella M.

Neurology. 2018 Jul 10;91(2):e153-e161. doi: 10.1212/WNL.0000000000005772. Epub 2018 Jun 6.

PMID:
29875218
12.

Balance worsening associated with nabiximols in multiple sclerosis.

Castelli L, Prosperini L, Pozzilli C.

Mult Scler. 2018 Mar 1:1352458518765649. doi: 10.1177/1352458518765649. [Epub ahead of print]

PMID:
29533137
13.

The Prevalence of Multiple Sclerosis in the Metropolitan Area of Rome: A Capture-Recapture Analysis.

Farcomeni A, Cortese A, Sgarlata E, Alunni Fegatelli D, Marfia GA, Buttari F, Mirabella M, De Fino C, Prosperini L, Pozzilli C, Grasso MG, Iasevoli L, Di Battista G, Millefiorini E.

Neuroepidemiology. 2018;50(3-4):105-110. doi: 10.1159/000487005. Epub 2018 Mar 2.

PMID:
29502114
14.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e823-e831. doi: 10.1212/WNL.0000000000005067. Epub 2018 Feb 7.

PMID:
29438046
15.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.

Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Solaro C, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e832-e839. doi: 10.1212/WNL.0000000000005068. Epub 2018 Feb 7.

PMID:
29438041
16.

Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management.

Fernández O, Delvecchio M, Edan G, Fredrikson S, Giovannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G.

Eur J Neurol. 2018 May;25(5):739-746. doi: 10.1111/ene.13581. Epub 2018 Feb 28.

PMID:
29356206
17.

Correction to: Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.

Amato MP, Bertolotto A, Brunelli R, Cavalla P, Goretti B, Marrosu MG, Patti F, Pozzilli C, Provinciali L, Rizzo N, Strobelt N, Tedeschi G, Trojano M, Comi G.

Neurol Sci. 2018 Feb;39(2):395. doi: 10.1007/s10072-017-3226-9.

PMID:
29280018
18.

Role of Cerebellar Dentate Functional Connectivity in Balance Deficits in Patients with Multiple Sclerosis.

Tona F, De Giglio L, Petsas N, Sbardella E, Prosperini L, Upadhyay N, Giannì C, Pozzilli C, Pantano P.

Radiology. 2018 Apr;287(1):267-275. doi: 10.1148/radiol.2017170311. Epub 2017 Dec 22.

PMID:
29272214
19.

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).

Comi G, Patti F, Rocca MA, Mattioli FC, Amato MP, Gallo P, Centonze D, Pozzilli C, Saccà F, Bergh FT, Bartezaghi M, Turrini R, Filippi M; Golden Study Group.

J Neurol. 2017 Dec;264(12):2436-2449. doi: 10.1007/s00415-017-8642-5. Epub 2017 Oct 23.

20.

The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study.

Pappalardo A, Chisari CG, Montanari E, Pesci I, Borriello G, Pozzilli C, D'Amico E, Patti F.

Mult Scler Relat Disord. 2017 Oct;17:154-171. doi: 10.1016/j.msard.2017.07.022. Epub 2017 Jul 28.

PMID:
29055451
21.

Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.

Rossi F, Prosperini L, De Rossi N, Capra R, Rivanera D, Li X, Cinque P, Passeri L, Pozzilli C, Viscidi R.

Viral Immunol. 2017 Oct;30(8):622-626. doi: 10.1089/vim.2017.0039. Epub 2017 Aug 24.

PMID:
28836899
22.

Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy.

Colais P, Agabiti N, Davoli M, Buttari F, Centonze D, De Fino C, Di Folco M, Filippini G, Francia A, Galgani S, Gasperini C, Giuliani M, Mirabella M, Nociti V, Pozzilli C, Bargagli A; Multiple Sclerosis Study Group, Lazio Region.

Neuroepidemiology. 2017;48(3-4):171-178. doi: 10.1159/000479515. Epub 2017 Aug 9.

PMID:
28793295
23.

Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.

Amato MP, Bertolotto A, Brunelli R, Cavalla P, Goretti B, Marrosu MG, Patti F, Pozzilli C, Provinciali L, Rizzo N, Strobelt N, Tedeschi G, Trojano M, Comi G.

Neurol Sci. 2017 Oct;38(10):1849-1858. doi: 10.1007/s10072-017-3081-8. Epub 2017 Aug 2. Erratum in: Neurol Sci. 2017 Dec 26;:.

PMID:
28770366
24.

Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study.

Latino P, Castelli L, Prosperini L, Marchetti MR, Pozzilli C, Giovannelli M.

Neurol Sci. 2017 Oct;38(10):1841-1848. doi: 10.1007/s10072-017-3078-3. Epub 2017 Aug 1.

PMID:
28766025
25.

High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline.

Gaetani L, Fanelli F, Riccucci I, Eusebi P, Sarchielli P, Pozzilli C, Calabresi P, Prosperini L, Di Filippo M.

J Neurol Sci. 2017 Aug 15;379:236-240. doi: 10.1016/j.jns.2017.06.008. Epub 2017 Jun 9.

PMID:
28716249
26.

Prognostic indicators in pediatric clinically isolated syndrome.

Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry.

Ann Neurol. 2017 May;81(5):729-739. doi: 10.1002/ana.24938.

PMID:
28439957
27.

Survey of diagnostic and treatment practices for multiple sclerosis in Europe.

Fernández O, Delvecchio M, Edan G, Fredrikson S, Gionvannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G.

Eur J Neurol. 2017 Mar;24(3):516-522. doi: 10.1111/ene.13236. Epub 2017 Jan 31.

PMID:
28139062
28.

Effect on Cognition of Estroprogestins Combined with Interferon Beta in Multiple Sclerosis: Analysis of Secondary Outcomes from a Randomised Controlled Trial.

De Giglio L, Marinelli F, Barletta VT, Pagano VA, De Angelis F, Fanelli F, Petsas N, Pantano P, Tomassini V, Pozzilli C.

CNS Drugs. 2017 Feb;31(2):161-168. doi: 10.1007/s40263-016-0401-0.

PMID:
27995531
29.

Extratemporal herpes encephalitis during natalizumab treatment: A case report.

Haggiag S, Prosperini L, Galgani S, Pozzilli C, Pinnetti C.

Mult Scler Relat Disord. 2016 Nov;10:134-136. doi: 10.1016/j.msard.2016.10.002. Epub 2016 Oct 5.

PMID:
27919480
30.

Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.

Prosperini L, Saccà F, Cordioli C, Cortese A, Buttari F, Pontecorvo S, Bianco A, Ruggieri S, Haggiag S, Brescia Morra V, Capra R, Centonze D, Di Battista G, Ferraro E, Francia A, Galgani S, Gasperini C, Millefiorini E, Mirabella M, Pozzilli C.

J Neurol. 2017 Feb;264(2):284-294. doi: 10.1007/s00415-016-8343-5. Epub 2016 Nov 22.

PMID:
27878443
31.

Corpus callosum microstructural changes associated with Kawashima Nintendo Brain Training in patients with multiple sclerosis.

De Giglio L, Upadhyay N, De Luca F, Prosperini L, Tona F, Petsas N, Pozzilli C, Pantano P.

J Neurol Sci. 2016 Nov 15;370:211-213. doi: 10.1016/j.jns.2016.09.041. Epub 2016 Sep 22. No abstract available.

PMID:
27772761
32.

Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.

Laroni A, Brogi D, Brescia Morra V, Guidi L, Pozzilli C, Comi G, Lugaresi A, Turrini R, Raimondi D, Uccelli A, Mancardi GL.

Neurol Sci. 2017 Jan;38(1):53-59. doi: 10.1007/s10072-016-2701-z. Epub 2016 Oct 18.

PMID:
27757552
33.

A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta.

Galassi S, Prosperini L, Logoteta A, Hirsch MN, Fanelli F, De Giglio L, Pozzilli C.

Mult Scler Relat Disord. 2016 Jul;8:99-106. doi: 10.1016/j.msard.2016.05.012. Epub 2016 May 17.

PMID:
27456883
34.

Tp-Te interval predicts heart rate reduction after fingolimod administration in patients with multiple sclerosis.

Tocci G, Giuliani M, Canichella F, Timpano J, Presta V, Francia P, Musumeci MB, Fubelli F, Pozzilli C, Volpe M, Ferrucci A.

Int J Cardiol. 2016 Oct 15;221:881-5. doi: 10.1016/j.ijcard.2016.07.134. Epub 2016 Jul 9.

PMID:
27434365
35.

Dentate nucleus connectivity in adult patients with multiple sclerosis: functional changes at rest and correlation with clinical features.

Sbardella E, Upadhyay N, Tona F, Prosperini L, De Giglio L, Petsas N, Pozzilli C, Pantano P.

Mult Scler. 2017 Apr;23(4):546-555. doi: 10.1177/1352458516657438. Epub 2016 Jul 18.

PMID:
27411700
36.

The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.

D'Amico E, Leone C, Graziano G, Amato MP, Bergamaschi R, Cavalla P, Coniglio G, Di Battista G, Ferrò MT, Granella F, Granieri E, Lugaresi A, Lus G, Millefiorini E, Pozzilli C, Tedeschi G, Zappia M, Comi G, Trojano M, Lepore V, Patti F.

PLoS One. 2016 Jun 27;11(6):e0157721. doi: 10.1371/journal.pone.0157721. eCollection 2016.

37.

Assessing response to interferon-β in a multicenter dataset of patients with MS.

Sormani MP, Gasperini C, Romeo M, Rio J, Calabrese M, Cocco E, Enzingher C, Fazekas F, Filippi M, Gallo A, Kappos L, Marrosu MG, Martinelli V, Prosperini L, Rocca MA, Rovira A, Sprenger T, Stromillo ML, Tedeschi G, Tintorè M, Tortorella C, Trojano M, Montalban X, Pozzilli C, Comi G, De Stefano N; MAGNIMS study group.

Neurology. 2016 Jul 12;87(2):134-40. doi: 10.1212/WNL.0000000000002830. Epub 2016 Jun 15.

PMID:
27306626
38.

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.

Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, MacManus DG, Yousry TA, Pozzilli C, Selmaj K, Sweetser MT, Zhang R, Yang M, Potts J, Novas M, Miller DH, Kurukulasuriya NC, Fox RJ, Phillips TJ.

Mult Scler. 2017 Feb;23(2):253-265. doi: 10.1177/1352458516649037. Epub 2016 Jul 11.

39.

A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.

Truini A, Prosperini L, Calistri V, Fiorelli M, Pozzilli C, Millefiorini E, Frontoni M, Cortese A, Caramia F, Cruccu G.

Neurology. 2016 May 31;86(22):2094-9. doi: 10.1212/WNL.0000000000002720. Epub 2016 May 4.

PMID:
27164695
40.

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.

Patti F, Messina S, Solaro C, Amato MP, Bergamaschi R, Bonavita S, Bruno Bossio R, Brescia Morra V, Costantino GF, Cavalla P, Centonze D, Comi G, Cottone S, Danni M, Francia A, Gajofatto A, Gasperini C, Ghezzi A, Iudice A, Lus G, Maniscalco GT, Marrosu MG, Matta M, Mirabella M, Montanari E, Pozzilli C, Rovaris M, Sessa E, Spitaleri D, Trojano M, Valentino P, Zappia M; SA.FE. study group.

J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):944-51. doi: 10.1136/jnnp-2015-312591. Epub 2016 May 9.

41.

Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis.

Prosperini L, Fanelli F, Pozzilli C.

J Neurol Sci. 2016 May 15;364:145-7. doi: 10.1016/j.jns.2016.03.025. Epub 2016 Mar 16.

PMID:
27084235
42.

The effect of inflammation and its reduction on brain plasticity in multiple sclerosis: MRI evidence.

Tomassini V, d'Ambrosio A, Petsas N, Wise RG, Sbardella E, Allen M, Tona F, Fanelli F, Foster C, Carnì M, Gallo A, Pantano P, Pozzilli C.

Hum Brain Mapp. 2016 Jul;37(7):2431-45. doi: 10.1002/hbm.23184. Epub 2016 Mar 18.

43.

Multiple Sclerosis: Changes in Thalamic Resting-State Functional Connectivity Induced by a Home-based Cognitive Rehabilitation Program.

De Giglio L, Tona F, De Luca F, Petsas N, Prosperini L, Bianchi V, Pozzilli C, Pantano P.

Radiology. 2016 Jul;280(1):202-11. doi: 10.1148/radiol.2016150710. Epub 2016 Mar 8.

PMID:
26953867
44.

Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems.

Bargagli AM, Colais P, Agabiti N, Mayer F, Buttari F, Centonze D, Di Folco M, Filippini G, Francia A, Galgani S, Gasperini C, Giuliani M, Mirabella M, Nociti V, Pozzilli C, Davoli M.

J Neurol. 2016 Apr;263(4):751-9. doi: 10.1007/s00415-016-8049-8. Epub 2016 Feb 17.

45.

The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis.

Pastò L, Portaccio E, Goretti B, Ghezzi A, Lori S, Hakiki B, Giannini M, Righini I, Razzolini L, Niccolai C, Moiola L, Falautano M, Simone M, Viterbo RG, Patti F, Cilia S, Pozzilli C, Bianchi V, Roscio M, Martinelli V, Comi G, Trojano M, Amato MP; MS Study Group of the Italian Neurological Society.

Mult Scler. 2016 Nov;22(13):1741-1749. Epub 2016 Feb 11.

PMID:
26869527
46.

No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).

Lanzillo R, Quarantelli M, Pozzilli C, Trojano M, Amato MP, Marrosu MG, Francia A, Florio C, Orefice G, Tedeschi G, Bellantonio P, Annunziata P, Grimaldi LM, Comerci M, Brunetti A, Bonavita V, Alfano B, Marini S, Brescia Morra V; ARIANNA study group.

Mult Scler. 2016 Aug;22(9):1163-73. doi: 10.1177/1352458515611222. Epub 2015 Oct 14.

PMID:
26466947
47.

Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.

Macdonell R, Nagels G, Laplaud DA, Pozzilli C, de Jong B, Martins da Silva A, Nicholas R, Lechner-Scott J, Gaebler JA, Agarwal S, Wang P, Yeh M, Hovenden M, Soelberg Sørensen P.

Mult Scler. 2016 Jun;22(7):944-54. doi: 10.1177/1352458515606809. Epub 2015 Oct 7.

PMID:
26447066
48.

Natalizumab in the pediatric MS population: results of the Italian registry.

Ghezzi A, Moiola L, Pozzilli C, Brescia-Morra V, Gallo P, Grimaldi LM, Filippi M, G GC; MS Study Group-Italian Society of Neurology.

BMC Neurol. 2015 Sep 25;15:174. doi: 10.1186/s12883-015-0433-y.

49.

An overview of pregnancy-related issues in patients with multiple sclerosis.

Pozzilli C, Pugliatti M; ParadigMS Group.

Eur J Neurol. 2015 Oct;22 Suppl 2:34-9. doi: 10.1111/ene.12797. Review.

PMID:
26374512
50.

Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.

Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore GB, Marrosu MG, Amato MP, Bertolotto A, Bergamaschi R, Granella F, Coniglio G, Tedeschi G, Sola P, Lus G, Ferrò MT, Iuliano G, Corea F, Protti A, Cavalla P, Guareschi A, Rodegher M, Paolicelli D, Tortorella C, Lepore V, Prosperini L, Saccà F, Baroncini D, Comi G, Trojano M; Italian iMed-Web database.

Brain. 2015 Nov;138(Pt 11):3275-86. doi: 10.1093/brain/awv260. Epub 2015 Sep 11.

PMID:
26362907

Supplemental Content

Loading ...
Support Center